Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10

Ruggero De Maria Marchiano, Giorgio Stassi, Matilde Todaro, Monica Zerilli, Lucia Ricci-Vitiani, Diana Di Liberto, Mariella Patti, Adamaria Florena, Francesca Di Gaudio, Giuseppe Di Gesù

Risultato della ricerca: Contributo in rivistaArticolo in rivista

110 Citazioni (Scopus)


We investigated the mechanisms responsible for the widespread refractoriness to chemotherapeutic drugs observed in thyroid cancers. We show that malignant epithelial cells from papillary, follicular, and anaplastic thyroid carcinomas express high levels of Bcl-2 and Bcl-xL. Exogenous expression of either Bcl-2 or Bcl-xL in normal thyrocytes was sufficient to prevent chemotherapeutic drug-induced cytotoxicity. All of the histological thyroid cancer variants examined produced interleukin-4 (IL-4) and interleukin-10 (IL-10), which increased Bcl-2 and Bcl-xL levels and protected thyroid cells from chemotherapeutic agents. Exposure to neutralizing antibodies against IL-4 and IL-10 resulted in down-modulation of Bcl-2 and Bcl-xL, death of a considerable percentage of thyroid cancer cells, and sensitization of the residual tumor population to cytotoxic drug-induced apoptosis. In conclusion, autocrine production of IL-4 and IL-10 promotes thyroid tumor cell progression and resistance to chemotherapy through the up-regulation of antiapoptotic proteins. Thus, IL-4 and IL-10 may represent new therapeutic targets for the treatment of thyroid cancer.
Lingua originaleEnglish
pagine (da-a)6784-6790
Numero di pagine7
RivistaCancer Research
Stato di pubblicazionePubblicato - 2003


  • Cancer Research
  • Oncology


Entra nei temi di ricerca di 'Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10'. Insieme formano una fingerprint unica.

Cita questo